摘要
目的分析聚乙二醇干扰素、利巴韦林联合治疗慢性丙型肝炎的临床效果以及安全性。方法收集2013年1月～2015年12月间就诊的慢性丙肝患者30例，随机将其分为观察组和对照组，均15例。对照组使用利巴韦林联合干扰素治疗，观察组使用利巴韦林联合聚乙二醇干扰素治疗，观察比较两组患者的临床治疗效果。结果观察组治疗效果明显高于对照组治疗效果，并发症发生率明显低于对照组，差异均有统计学意义（P＜0.05）。结论聚乙二醇干扰素联合利巴韦林对慢性丙肝的治疗效果明显优于常规干扰素联合利巴韦林，且安全性更好。
Objective To analyze the clinical efficacy and safety of combination therapy with PEG interferon and ribavirin in the treatment of chronichepatitis C. Methods From January 2013 to December 2015, 30 cases of chronic hepatitis C patients in our hospital were randomly divided into observationgroup and control group, 15 cases of each. The patients of control group were given ribavirin combined interferon treatment, and the patients of observationgroup were given pegylated interferon and ribavirin in the treatment of chronic hepatitis C. Then compared the curative effect. Results The treatment effect ofobservation group was obviously higher than that of the control group, and the complication rate of observation group was significantly lower than that of thecontrol group, the difference was statistically significant( P < 0.05). Conclusion The treatment effect of the Pegylated interferon plus ribavirin in patientswith chronic hepatitis C is obviously superior to the conventional interferon plus ribavirin with better safety.
作者
付敏
FU Min(Department of infectious diseases in Jiangsu city of Xuzhou Province Mining Group general hospital ward 29, Jiangsu Xuzhou 221000, China)
出处
《中国处方药》
2016年第10期49-50,共2页
Journal of China Prescription Drug
